(Q28290823)
Statements
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study (English)
0 references
September 2008
0 references
7
0 references
9
0 references
796-804
0 references